{
    "nct_id": "NCT05642962",
    "official_title": "A Randomized Double Blind Study of Pancreatic Enzyme Replacement Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma",
    "inclusion_criteria": "* Histopathologic or cytologic diagnosis of pancreatic adenocarcinoma, or adenosquamous cancer, or any non-neuroendocrine primary pancreas variant, including acinar cancer.\n* De novo or recurrent diagnosis of previously untreated stage IV PDAC with intent to receive FOLFIRINOX/mFOLFIRINOX.\n* ECOG 0-2.\n* No use of pancreatic enzyme replacement therapy within prior 2 weeks.\n* Patients with biliary obstruction are eligible provided biliary stenting has or will occur before treatment with FOLFIRINOX.\n* Ability to understand and the willingness to sign an informed consent document.\n* Ability to swallow capsules.\n* Age â‰¥18 years.\n* Anticipated life expectancy of at least 6 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Chronic illness associated with malabsorption (celiac disease, cystic fibrosis, chronic pancreatitis, Crohn's disease).\n* Fibrosing colonopathy.\n* Prior history of surgical resection of the pancreas or gastric bypass.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Pancrelipase.\n* Patients cannot receive radiation, IRE, or other localized therapy directed to the pancreas while on study.",
    "miscellaneous_criteria": ""
}